Moderna confirmed talks with Japan on the availability of the experimental vaccine COVID-19 vaccine.

Moderna said recently that it is in talks with the Japanese government about a potential pre-purchase agreement to buy 40 million or more doses of the experimental COVID-19 vaccine (mRNA-1273).
if mRNA-1273 is approved by regulators, the vaccine will be provided by Moderna and distributed by Takeda Pharmaceuticals in Japan, with an expected first half of 2021.
vaccine mRNA-1273 was developed by the National Institute of Allergy and Infectious Diseases (NIAID) and Moderna.
mRNA-1273, manufactured by Moderna, is designed to induce the naming of antibodies, which point to part of the coronavirus "prick" protein, which binds to and enters human cells using prickly proteins.
Japan has signed agreements with companies such as AstraZeneca and Pfizer, as well as Shionogi, to get 521 million doses of five different COVID-19 vaccines by 2021.
health minister said Japan plans to launch the COVID-19 vaccine in June next year.
previously signed a $1.5 billion deal with the United States to provide 100 million doses of mRNA-1273.
, the company recently concluded exploratory talks with the European Union, which will buy 80 million doses of mRNA-1273 and have the option to buy another 80 million.
earlier this month, Moderna presented interim data from the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practice Phase I study, which showed that mRNA-1273 is safe and produces an immune response in people over 55 years of age, including older subjects.
.